Follow The Filings

DNTH Dianthus Therapeutics Inc.

Health Care, filed as DIANTHUS THERAPEUTICS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q2, sold by 1

  • 2 Owners
  • Max 32.9%
  • $206M
  • 1 add 1 exit

In 2026 Q2 Polen Capital Management added to Dianthus Therapeutics, while Farallon Capital Management sold out.

Who owns this now

Largest portfolio weights among holders, up to 32.9% (David Witzke, Avidity Partners Management). Not free-float ownership.

  1. David Witzke 32.9%
  2. Polen Capital Management Add 0.01%

Who owns DNTH

Sorted by value, long equity only, as of 2026 Q2.

History
David Witzke, Avidity Partners Management 32.9% Hold 2,104,184 $205M History
Polen Capital Management 0.01% Add +126.6% 9,333 $910K History
Farallon Capital Management exited 2026 Q2 Last 2026 Q1 0.40% Exit −0.40% 836,000 $70M History

2 current, 1 exited last period, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by DNTH's executives, directors and 10% owners in the last 12 months, from their Form 4s

All DNTH insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • $71.2M sold by 8 insiders under 10b5-1 plans
  1. Edward Carr Chief Accounting Officer
    Planned sale
    $2M 20,000 shares at $101.38 100% of stake
    Traded Sep 17 Filed Sep 18
    ↗
  2. Simrat Randhawa EVP, Head of R&D
    Planned sale
    $2.5M 23,124 shares at $106.41 85% of stake
    Traded Sep 1 Filed Sep 3
    ↗
  3. Simon Read Director
    Planned sale
    $327K 2,778 shares at $117.55 100% of stake
    Traded Aug 19 Filed Aug 19
    ↗
  4. Anne McGeorge Director
    Planned sale
    $845K 7,750 shares at $109.01 100% of stake
    Traded Aug 10 Filed Aug 11
    ↗
  5. Adam M Veness SVP, General Counsel and Sec.
    Planned sale
    $2.2M 20,000 shares at $110.44 100% of stake
    Traded Aug 7–10 Filed Aug 11
    ↗
  6. Simon Read Director
    Planned sale
    $304K 2,777 shares at $109.55 100% of stake
    Traded Aug 10 Filed Aug 11
    ↗
  7. Marino Garcia CEO
    Planned sale
    $17.9M 166,000 shares at $108.11 72% of stake
    Traded Aug 7 Filed Aug 7
    ↗
  8. Ryan Savitz CFO
    Planned sale
    $3.2M 31,249 shares at $101.03 100% of stake
    Traded Jul 9 Filed Jul 13
    ↗
  9. Adam M Veness SVP, General Counsel and Sec.
    Planned sale
    $2.4M 30,000 shares at $80.80 100% of stake
    Traded Jun 17 Filed Jun 18
    ↗
  10. Simrat Randhawa EVP, Head of R&D
    Planned sale
    $2.4M 26,530 shares at $90.62 87% of stake
    Traded Jun 1 Filed Jun 2
    ↗
  11. Paula Soteropoulos Director
    Planned sale
    $51K 599 shares at $85.47 100% of stake
    Traded May 8 Filed May 11
    ↗
  12. Ryan Savitz CFO
    Planned sale
    $739K 8,224 shares at $89.84 100% of stake
    Traded Apr 9 Filed Apr 10
    ↗
  13. Ryan Savitz CFO
    Planned sale
    $9.5M 114,367 shares at $83.00 100% of stake
    Traded Mar 31 Filed Apr 1
    ↗
  14. Paula Soteropoulos Director
    Planned sale
    $48K 599 shares at $80.11 100% of stake
    Traded Mar 31 Filed Apr 1
    ↗
  15. Paula Soteropoulos Director
    Planned sale
    $2.2M 27,594 shares at $78.05 100% of stake
    Traded Mar 24 Filed Mar 26
    ↗

Also filed in the last 12 months, not counted as buying or selling: 41 option exercises.

SEC filings

Recent issuer filings from EDGAR, 20 shown.

Filed Form Detail Links
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 5.07 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G — Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc

Source: SEC EDGAR submissions, updated 2 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue — $6.24M $2.04M
Net income -$43.56M -$84.97M -$162.34M
Net margin * — -1362.8% -7973.3%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $177.45M $280.9M $409.44M
Total non-current assets * $1.95M $93.1M $121.48M
Total assets $179.4M $374.01M $530.92M
Total current liabilities $9.63M $18.45M $30.73M
Total non-current liabilities * $0.904M $3.08M $6.79M
Total equity $168.87M $352.48M $493.4M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$36.86M -$78.18M -$129.06M
Cash from investing $20.25M -$286.81M -$122.83M
Cash from financing $133.57M $255.62M $280.12M
Net change in cash $116.97M -$109.37M $28.23M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

More on the shelf